SWK Holdings Corp
NASDAQ:SWKH
Net Margin
SWK Holdings Corp
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
S
|
SWK Holdings Corp
NASDAQ:SWKH
|
221.2m USD |
30%
|
|
| IN |
|
Indian Railway Finance Corp Ltd
NSE:IRFC
|
1.7T INR |
24%
|
|
| IN |
|
Power Finance Corporation Ltd
NSE:PFC
|
1.4T INR |
22%
|
|
| IN |
|
REC Limited
NSE:RECLTD
|
1.1T INR |
29%
|
|
| JP |
|
Shinkin Central Bank
TSE:8421
|
1.8T JPY |
9%
|
|
| JP |
|
Mitsubishi HC Capital Inc
TSE:8593
|
1.4T JPY |
6%
|
|
| CA |
|
Element Fleet Management Corp
TSX:EFN
|
12.1B CAD |
18%
|
|
| TW |
|
Chailease Holding Company Ltd
TWSE:5871
|
187.1B TWD |
22%
|
|
| IN |
I
|
Indian Renewable Energy Development Agency Ltd
NSE:IREDA
|
466.7B INR |
25%
|
|
| IN |
|
Housing and Urban Development Corporation Ltd
NSE:HUDCO
|
461.7B INR |
28%
|
|
| JP |
|
Tokyo Century Corp
TSE:8439
|
709.1B JPY |
6%
|
SWK Holdings Corp
Glance View
SWK Holdings Corp. is engaged in the business of financial and asset management in the field of pharmaceutical. The company is headquartered in Dallas, Texas and currently employs 35 full-time employees. The firm is focused on providing various capital solutions to a range of life science companies, institutions and inventors. The firm operates through two segments: Finance Receivables and Pharmaceutical Development. Its Finance Receivables segment is primarily focused on monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. In addition, through its wholly owned subsidiary, SWK Advisors LLC, it provides non-discretionary investment advisory services to institutional clients in separately managed accounts to similarly invest in life science finance. Through its subsidiary, Enteris BioPharma, Inc., its Pharmaceutical Development segment offers formulation solutions built around its oral drug delivery technology, the Peptelligence platform.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on SWK Holdings Corp's most recent financial statements, the company has Net Margin of 30%.
You don't have any saved screeners yet